

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Lee's Pharmaceutical Holdings Limited

李氏大藥廠控股有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 950)

POSITIVE PROFIT ALERT

This announcement is made by Lee's Pharmaceutical Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong).

The board of directors of the Company (the "**Board**") wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors of the Company that, based on the preliminary assessment of the Group's unaudited financial information currently available, it is anticipated that the unaudited net profit attributable to the Shareholders for the year ended 31 December 2018 will increase by about 50%, as compared to that of for the year ended 31 December 2017. The net profit increase was primarily due to a non-recurring gain recognised from the deemed disposal of interests in CVie Therapeutics Limited in December 2018. CVie Therapeutics Limited is an associate of the Group based in Taiwan which engaging in the development of certain cardiovascular disease drugs.

The Company is still in the process of finalising the Group's final results for the year ended 31 December 2018. The information contained in this announcement is only a preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended 31 December 2018 which have not been audited or reviewed by the external auditors of the Company. The Company's annual results for the year ended 31 December 2018 is expected to be announced by the end of March 2019.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Lee's Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

Hong Kong, 4 March 2019

** For identification purpose only*

As at the date of this announcement, Ms. Lee Siu Fong (Chairman), Ms. Leelalertsuphakun Wanee and Dr. Li Xiaoyi are executive directors of the Company; Mr. Simon Miles Ball is a non-executive director of the Company; Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl are independent non-executive directors of the Company.